Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cellectar Biosc (CLRB)

Cellectar Biosc (CLRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cellectar Biosciences Announces Phase 2 CLOVER-WaM Study Data Selected for Presentation at ASH Meeting and Financial Results for Q3 2024

Cellectar Biosciences announced Phase 2 study results and fundraising efforts, preparing for NDA submission for iopofosine I 131.Quiver AI SummaryCellectar Biosciences, Inc. announced significant advancements...

CLRB : 1.77 (-4.84%)
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

CLRBZ : 0.12 (-14.27%)
CLRB : 1.77 (-4.84%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

CLRBZ : 0.12 (-14.27%)
CLRB : 1.77 (-4.84%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

CLRBZ : 0.12 (-14.27%)
CLRB : 1.77 (-4.84%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

CLRBZ : 0.12 (-14.27%)
CLRB : 1.77 (-4.84%)
CLRBW : 0.13 (+348.28%)
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

CLRB : 1.77 (-4.84%)
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

CLRB : 1.77 (-4.84%)
Cellectar Reports Financial Results for Second Quarter 2022

FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the...

CLRB : 1.77 (-4.84%)
Cellectar Announces Stock Consolidation

FLORHAM PARK, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage biopharmaceutical company focused on the...

CLRB : 1.77 (-4.84%)
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...

CLRB : 1.77 (-4.84%)

Barchart Exclusives

Is It Time to Buy This Dividend Stock With Nuclear Energy Upside?
Apart from its prowess in nuclear energy, this energy company is also deploying AI. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar